VERTEX PHARMACEUTICALS INC (1VRTX.MI) Stock Fundamental Analysis
Europe - BIT:1VRTX - US92532F1003 - Common Stock
334.7 EUR
-2.05 (-0.61%)
Taking everything into account, 1VRTX scores 7 out of 10 in our fundamental rating. 1VRTX was compared to 75 industry peers in the Biotechnology industry. 1VRTX scores excellent points on both the profitability and health parts. This is a solid base for a good stock. 1VRTX is growing strongly while it is still valued neutral. This is a good combination! With these ratings, 1VRTX could be worth investigating further for growth and quality investing!.
1. Profitability
1.1 Basic Checks
In the past year 1VRTX was profitable.
In the past year 1VRTX had a positive cash flow from operations.
Of the past 5 years 1VRTX 4 years were profitable.
1VRTX had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
1VRTX's Return On Assets of 15.13% is amongst the best of the industry. 1VRTX outperforms 86.67% of its industry peers.
1VRTX's Return On Equity of 21.18% is amongst the best of the industry. 1VRTX outperforms 88.00% of its industry peers.
Looking at the Return On Invested Capital, with a value of 16.69%, 1VRTX belongs to the top of the industry, outperforming 90.67% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for 1VRTX is above the industry average of 13.78%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 15.13% | ||
| ROE | 21.18% | ||
| ROIC | 16.69% |
ROA(3y)10.62%
ROA(5y)14.47%
ROE(3y)13.73%
ROE(5y)19.12%
ROIC(3y)18.67%
ROIC(5y)19.24%
1.3 Margins
1VRTX has a Profit Margin of 31.86%. This is amongst the best in the industry. 1VRTX outperforms 86.67% of its industry peers.
With an excellent Operating Margin value of 38.77%, 1VRTX belongs to the best of the industry, outperforming 92.00% of the companies in the same industry.
In the last couple of years the Operating Margin of 1VRTX has grown nicely.
1VRTX has a better Gross Margin (86.11%) than 74.67% of its industry peers.
1VRTX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 38.77% | ||
| PM (TTM) | 31.86% | ||
| GM | 86.11% |
OM growth 3Y2.79%
OM growth 5Y6.75%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y-0.17%
2. Health
2.1 Basic Checks
1VRTX has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
1VRTX has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, 1VRTX has less shares outstanding
Compared to 1 year ago, 1VRTX has an improved debt to assets ratio.
2.2 Solvency
There is no outstanding debt for 1VRTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | N/A |
ROIC/WACC1.74
WACC9.58%
2.3 Liquidity
1VRTX has a Current Ratio of 2.52. This indicates that 1VRTX is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of 1VRTX (2.52) is comparable to the rest of the industry.
1VRTX has a Quick Ratio of 2.16. This indicates that 1VRTX is financially healthy and has no problem in meeting its short term obligations.
1VRTX has a Quick ratio (2.16) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.52 | ||
| Quick Ratio | 2.16 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 7966.67% over the past year.
The earnings per share for 1VRTX have been decreasing by -44.14% on average. This is quite bad
The Revenue has grown by 10.46% in the past year. This is quite good.
The Revenue has been growing by 21.50% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)7966.67%
EPS 3Y-71.86%
EPS 5Y-44.14%
EPS Q2Q%135.23%
Revenue 1Y (TTM)10.46%
Revenue growth 3Y13.31%
Revenue growth 5Y21.5%
Sales Q2Q%12.06%
3.2 Future
Based on estimates for the next years, 1VRTX will show a very strong growth in Earnings Per Share. The EPS will grow by 151.19% on average per year.
Based on estimates for the next years, 1VRTX will show a quite strong growth in Revenue. The Revenue will grow by 10.04% on average per year.
EPS Next Y6256.61%
EPS Next 2Y749.77%
EPS Next 3Y329.69%
EPS Next 5Y151.19%
Revenue Next Year10.07%
Revenue Next 2Y9.8%
Revenue Next 3Y9.48%
Revenue Next 5Y10.04%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 23.36, which indicates a rather expensive current valuation of 1VRTX.
80.00% of the companies in the same industry are more expensive than 1VRTX, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 27.41, 1VRTX is valued at the same level.
1VRTX is valuated rather expensively with a Price/Forward Earnings ratio of 18.89.
Based on the Price/Forward Earnings ratio, 1VRTX is valued cheaper than 81.33% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.88, 1VRTX is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 23.36 | ||
| Fwd PE | 18.89 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, 1VRTX is valued a bit cheaper than 76.00% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, 1VRTX is valued a bit cheaper than 78.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 28.98 | ||
| EV/EBITDA | 20.54 |
4.3 Compensation for Growth
1VRTX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of 1VRTX may justify a higher PE ratio.
1VRTX's earnings are expected to grow with 329.69% in the coming years. This may justify a more expensive valuation.
PEG (NY)0
PEG (5Y)N/A
EPS Next 2Y749.77%
EPS Next 3Y329.69%
5. Dividend
5.1 Amount
1VRTX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIT:1VRTX (9/10/2025, 7:00:00 PM)
334.7
-2.05 (-0.61%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners97.63%
Inst Owner ChangeN/A
Ins Owners0.13%
Ins Owner ChangeN/A
Market Cap85.81B
Analysts75
Price Target425.83 (27.23%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.87%
Min EPS beat(2)-7.2%
Max EPS beat(2)3.45%
EPS beat(4)2
Avg EPS beat(4)-0.78%
Min EPS beat(4)-7.2%
Max EPS beat(4)3.69%
EPS beat(8)5
Avg EPS beat(8)-64.35%
EPS beat(12)7
Avg EPS beat(12)-42%
EPS beat(16)10
Avg EPS beat(16)-30.64%
Revenue beat(2)1
Avg Revenue beat(2)-2.37%
Min Revenue beat(2)-4.8%
Max Revenue beat(2)0.06%
Revenue beat(4)2
Avg Revenue beat(4)-0.57%
Min Revenue beat(4)-4.8%
Max Revenue beat(4)2.68%
Revenue beat(8)3
Avg Revenue beat(8)-0.87%
Revenue beat(12)5
Avg Revenue beat(12)-0.45%
Revenue beat(16)8
Avg Revenue beat(16)0.05%
PT rev (1m)-2.99%
PT rev (3m)-9.41%
EPS NQ rev (1m)0.02%
EPS NQ rev (3m)1.8%
EPS NY rev (1m)0.71%
EPS NY rev (3m)-0.04%
Revenue NQ rev (1m)0.35%
Revenue NQ rev (3m)1.4%
Revenue NY rev (1m)0.46%
Revenue NY rev (3m)0.25%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 23.36 | ||
| Fwd PE | 18.89 | ||
| P/S | 8.88 | ||
| P/FCF | 28.98 | ||
| P/OCF | 26.37 | ||
| P/B | 5.9 | ||
| P/tB | 6.48 | ||
| EV/EBITDA | 20.54 |
EPS(TTM)14.33
EY4.28%
EPS(NY)17.72
Fwd EY5.29%
FCF(TTM)11.55
FCFY3.45%
OCF(TTM)12.69
OCFY3.79%
SpS37.69
BVpS56.68
TBVpS51.66
PEG (NY)0
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 15.13% | ||
| ROE | 21.18% | ||
| ROCE | 22.25% | ||
| ROIC | 16.69% | ||
| ROICexc | 24.57% | ||
| ROICexgc | 27.69% | ||
| OM | 38.77% | ||
| PM (TTM) | 31.86% | ||
| GM | 86.11% | ||
| FCFM | 30.65% |
ROA(3y)10.62%
ROA(5y)14.47%
ROE(3y)13.73%
ROE(5y)19.12%
ROIC(3y)18.67%
ROIC(5y)19.24%
ROICexc(3y)46.18%
ROICexc(5y)52.12%
ROICexgc(3y)66.07%
ROICexgc(5y)80.93%
ROCE(3y)24.89%
ROCE(5y)25.65%
ROICexcg growth 3Y-29.98%
ROICexcg growth 5Y-9.76%
ROICexc growth 3Y-22.64%
ROICexc growth 5Y-1.94%
OM growth 3Y2.79%
OM growth 5Y6.75%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y-0.17%
F-Score6
Asset Turnover0.48
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 173.52% | ||
| Cap/Sales | 3.04% | ||
| Interest Coverage | 260.41 | ||
| Cash Conversion | 83.13% | ||
| Profit Quality | 96.21% | ||
| Current Ratio | 2.52 | ||
| Quick Ratio | 2.16 | ||
| Altman-Z | N/A |
F-Score6
WACC9.58%
ROIC/WACC1.74
Cap/Depr(3y)171.61%
Cap/Depr(5y)187.83%
Cap/Sales(3y)3.11%
Cap/Sales(5y)3.32%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7966.67%
EPS 3Y-71.86%
EPS 5Y-44.14%
EPS Q2Q%135.23%
EPS Next Y6256.61%
EPS Next 2Y749.77%
EPS Next 3Y329.69%
EPS Next 5Y151.19%
Revenue 1Y (TTM)10.46%
Revenue growth 3Y13.31%
Revenue growth 5Y21.5%
Sales Q2Q%12.06%
Revenue Next Year10.07%
Revenue Next 2Y9.8%
Revenue Next 3Y9.48%
Revenue Next 5Y10.04%
EBIT growth 1Y4.24%
EBIT growth 3Y16.47%
EBIT growth 5Y29.7%
EBIT Next Year816.11%
EBIT Next 3Y130.8%
EBIT Next 5Y68.38%
FCF growth 1Y-9.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-5.45%
OCF growth 3YN/A
OCF growth 5YN/A